insights_auto
Why is DMN down ५.११%?
Dive Deeperchevron_right
DMN:FRA
Diamyd Medical AB
€ ०.०५९
arrow_downward
-५.११%(-०.००३२) 1D
नोभेम्बर २०, २२:००:०० GMT+१ · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DMN...
Open
€ ०.०६
High
€ ०.०६
Low
€ ०.०६
Mkt. cap
१३.५१ करोड
Avg. vol.
०.००
Volume
०.००
52-wk high
€ १.८०
52-wk low
€ ०.०५
No. of employees
४२
Open
€ ०.०६
High
€ ०.०६
Low
€ ०.०६
Mkt. cap
१३.५१ करोड
Avg. vol.
०.००
Volume
०.००
52-wk high
€ १.८०
52-wk low
€ ०.०५
No. of employees
४२
News stories
From web sources and news partners
The Motley Fool
·
५८ मिनेट पहिले
The S&P 500 Is 14 for 14 After Midterm Elections. Here’s How I’d Invest Now.
TradingKey
·
१० घण्टा पहिले
S&P 500 Falls Below 200-Day Moving Average: Buy-the-Dip Opportunity or Bear Market Warning?
Beinsure
·
१५ घण्टा पहिले
Vanguard S&P 500 ETF: How investing in VOO could build a $1 mn portfolio
StoneX
·
२ दिन पहिले
S&P 500, Nasdaq 100 Drive into Correction Territory
Profile
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
About Diamyd Medical AB